Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Alice T. Shaw, Yuankai Shi, Pan-Chyr Yang, Keith D. Wilner, Tommaso De Pas, Vera Hirsh, Javier de Castro Carpeño, Pasi A. Jänne, Jean-Charles Soria, Benjamin Solomon, Anna Polli, Fiona H Blackhall, Arlene Reisman, D. Ross Camidge, Tony Mok, Dong Wan Kim, Silvana Lanzalone, Toyoaki Hida, Shrividya Iyer
Publikováno v:
ESMO Open
Blackhall, F, Ross Camidge, D, Shaw, A T, Soria, J C, Solomon, B J, Mok, T, Hirsh, V, Jänne, P A, Shi, Y, Yang, P C, De Pas, T, Hida, T, De Castro Carpeño, J, Lanzalone, S, Polli, A, Iyer, S, Reisman, A, Wilner, K D & Kim, D W 2017, ' Final results of the large-scale multinational trial PROFILE 1005 : Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer ', ESMO Open, vol. 2, no. 3, e000219 . https://doi.org/10.1136/esmoopen-2017-000219
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blackhall, F, Ross Camidge, D, Shaw, A T, Soria, J C, Solomon, B J, Mok, T, Hirsh, V, Jänne, P A, Shi, Y, Yang, P C, De Pas, T, Hida, T, De Castro Carpeño, J, Lanzalone, S, Polli, A, Iyer, S, Reisman, A, Wilner, K D & Kim, D W 2017, ' Final results of the large-scale multinational trial PROFILE 1005 : Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer ', ESMO Open, vol. 2, no. 3, e000219 . https://doi.org/10.1136/esmoopen-2017-000219
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest